30 research outputs found
Síndrome de insuficiência androgênica: critérios diagnósticos e terapêuticos
The womens androgen insufficiency syndrome (AIS) arises, even nowadays, many debates and clears a lot of controversies. It is known, however, that the plasmatic levels of testosterone gradually decline through the reproductive period. AIS is appraised as a set of clinical symptoms, bioavailability presence diminished of testosterone and normal levels of estrogen. Among the main symptoms that remind the diagnosis are the well-being impairment, dysphoric mood, the fatigue without apparent cause, the sexual desire impairment, the loss of weight and the vasomotor instability in postmenopausal women receiving estrogen. These, however, are potentially attributable to the different etiologies and make it difficult to give the correct diagnosis in the majority of the cases, even though it is reminded, often, in patients who submit to bilateral oophorectomy. The diagnosis of the SIA seems to be essentially clinical, not having the needs of laboratorial dosages for its proof. It shouldnt indicate the androgenic therapy (AT) in patients without concomitant estrogen therapy. Testosterone is considered the ideal hormone for AT. Patients with suggestive SIA symptoms, excluded other identifiable causes, especially the post-menopauses ones, are candidates to AT. There are no safety data about AT in long stated period users. The transdermal patches, creams and gel seems to be preferable to the oral formulations.A síndrome da insuficiência androgênica na mulher (SIA) desperta, mesmo nos dias atuais, muitas discussões e encerra muitas controvérsias. Sabe-se, no entanto, que os níveis plasmáticos de testosterona declinam progressivamente ao longo do período reprodutivo. Conceitua-se a SIA como o conjunto de sintomas clínicos, a presença de biodisponibilidade diminuída de testosterona e os níveis normais de estrogênios. Entre os principais sintomas, citam-se o comprometimento do bem-estar, o humor disfórico, a fadiga sem causa aparente, o comprometimento do desejo sexual, o emagrecimento e a instabilidade vasomotora em mulheres pós-menopáusicas sob terapêutica estrogênica. Esses sintomas, no entanto, são potencialmente atribuíveis a diferentes etiologias e dificultam o correto diagnóstico na maioria dos casos, ainda que ele seja lembrado com freqüência em pacientes que se submetem à ooforectomia bilateral. O diagnóstico da SIA parece ser essencialmente clínico, não havendo a necessidade das dosagens laboratoriais para a sua comprovação. Não se deve indicar a terapêutica androgênica (TA) em pacientes que não estejam adequadamente estrogenizadas. Considera-se a testosterona o hormônio ideal para a TA. As pacientes com sintomas sugestivos de SIA, excluídas outras causas identificáveis, especialmente se pós-menopáusicas, são candidatas à TA. Não existem dados de segurança sobre a TA em usuárias em longo prazo. A via transdérmica - através de adesivos, cremes e gel - parece ser preferível à oral
Multicenter validation of PIM3 and PIM2 in Brazilian pediatric intensive care units
ObjectiveTo validate the PIM3 score in Brazilian PICUs and compare its performance with the PIM2.MethodsObservational, retrospective, multicenter study, including patients younger than 16 years old admitted consecutively from October 2013 to September 2019. We assessed the Standardized Mortality Ratio (SMR), the discrimination capability (using the area under the receiver operating characteristic curve – AUROC), and the calibration. To assess the calibration, we used the calibration belt, which is a curve that represents the correlation of predicted and observed values and their 95% Confidence Interval (CI) through all the risk ranges. We also analyzed the performance of both scores in three periods: 2013–2015, 2015–2017, and 2017–2019.Results41,541 patients from 22 PICUs were included. Most patients aged less than 24 months (58.4%) and were admitted for medical conditions (88.6%) (respiratory conditions = 53.8%). Invasive mechanical ventilation was used in 5.8%. The median PICU length of stay was three days (IQR, 2–5), and the observed mortality was 1.8% (763 deaths). The predicted mortality by PIM3 was 1.8% (SMR 1.00; 95% CI 0.94–1.08) and by PIM2 was 2.1% (SMR 0.90; 95% CI 0.83–0.96). Both scores had good discrimination (PIM3 AUROC = 0.88 and PIM2 AUROC = 0.89). In calibration analysis, both scores overestimated mortality in the 0%–3% risk range, PIM3 tended to underestimate mortality in medium-risk patients (9%–46% risk range), and PIM2 also overestimated mortality in high-risk patients (70%–100% mortality risk).ConclusionsBoth scores had a good discrimination ability but poor calibration in different ranges, which deteriorated over time in the population studied
The complete genome sequence of Chromobacterium violaceum reveals remarkable and exploitable bacterial adaptability
Chromobacterium violaceum is one of millions of species of free-living microorganisms that populate the soil and water in the extant areas of tropical biodiversity around the world. Its complete genome sequence reveals (i) extensive alternative pathways for energy generation, (ii) ≈500 ORFs for transport-related proteins, (iii) complex and extensive systems for stress adaptation and motility, and (iv) wide-spread utilization of quorum sensing for control of inducible systems, all of which underpin the versatility and adaptability of the organism. The genome also contains extensive but incomplete arrays of ORFs coding for proteins associated with mammalian pathogenicity, possibly involved in the occasional but often fatal cases of human C. violaceum infection. There is, in addition, a series of previously unknown but important enzymes and secondary metabolites including paraquat-inducible proteins, drug and heavy-metal-resistance proteins, multiple chitinases, and proteins for the detoxification of xenobiotics that may have biotechnological applications
The Genome of Anopheles darlingi, the main neotropical malaria vector
Anopheles darlingi is the principal neotropical malaria vector, responsible for more than a million cases of malaria per year on the American continent. Anopheles darlingi diverged from the African and Asian malaria vectors ∼100 million years ago (mya) and successfully adapted to the New World environment. Here we present an annotated reference A. darlingi genome, sequenced from a wild population of males and females collected in the Brazilian Amazon. A total of 10 481 predicted protein-coding genes were annotated, 72% of which have their closest counterpart in Anopheles gambiae and 21% have highest similarity with other mosquito species. In spite of a long period of divergent evolution, conserved gene synteny was observed between A. darlingi and A. gambiae. More than 10 million single nucleotide polymorphisms and short indels with potential use as genetic markers were identified. Transposable elements correspond to 2.3% of the A. darlingi genome. Genes associated with hematophagy, immunity and insecticide resistance, directly involved in vectorhuman and vectorparasite interactions, were identified and discussed. This study represents the first effort to sequence the genome of a neotropical malaria vector, and opens a new window through which we can contemplate the evolutionary history of anopheline mosquitoes. It also provides valuable information that may lead to novel strategies to reduce malaria transmission on the South American continent. The A. darlingi genome is accessible at www.labinfo.lncc.br/index.php/anopheles- darlingi. © 2013 The Author(s)
Vaginoplastia com utilização de enxerto de pele da região abdominal inferior
OBJETIVOS: apresentar técnica de vaginoplastia e avaliar os seus resultados e complicações. MÉTODOS: foram incluídas 20 mulheres portadoras de ausência congênita de vagina, atendidas no período de 1989 a 1996, com idades entre 19 e 39 anos. A metodização dos tempos cirúrgicos consistia na abertura de uma cavidade entre o reto e a bexiga e no seu revestimento com enxerto de pele de espessura total retirado da região abdominal inferior, sendo a cavidade mantida com o uso de um molde dilatador e a área doadora suturada em primeira intenção. RESULTADOS: morfologicamente, em 75, 85 e 80% dos casos as vaginas apresentaram bom revestimento epitelial, boa elasticidade e boa amplitude, respectivamente. Funcionalmente, em 80% dos casos o ato sexual foi considerado satisfatório por ambos os cônjuges. CONCLUSÕES: a técnica apresentada possibilitou a obtenção de uma vagina adequada do ponto de vista anatomofuncional, a cicatrização rápida da área doadora em primeira intenção com bom aspecto estético e um baixo nível de complicações
La última palabra en dosis mínima
In this article we rewiewed the indications of the low-dose hormone replacement therapy in post menopausal women. We evaluate the effects of this therapy on menopausal symptoms bone metabolism, cardiovascular risk and endometrial cancer. The low-dose hormone replacement therapy is satisfactory to relief menopausal symptoms and improves lipid profile preventing atherosclerosis. It does not increase the risk of hyperplasia or endometrial cancer when is associate with progestagens. The low dose hormone replacement therapy is also associate to improve bone mineral density but to have better comprehension about the effective action of the low dose hormone replacement therapy on bone, more studies evaluating the risk of fractures are necessary
Aspectos clínicos e metabólicos de mulheres na pós-menopausa tratadas com tibolona Clinical and metabolic aspects of postmenopausal women treated with tibolone
Objetivos: analisar a repercussão da tibolona sobre os sintomas do climatério e sobre algumas variáveis clínicas e metabólicas. Métodos: foram avaliadas 34 pacientes na pós-menopausa que foram submetidas ao tratamento com tibolona na dose de 2,5 mg/dia por 48 semanas. Foram analisados os seguintes parâmetros: peso, pressão arterial e perfis lipídico e lipoprotéico, representados pelos níveis de colesterol total, HDL-c, LDL-c, VLDL-c e triglicerídeos. Resultados: melhora relevante da sintomatologia do climatério foi demonstrada por decréscimo significativo do índice menopausal de Kupperman (p<0.001) e da freqüência média das ondas de calor (p<0.001). Estes efeitos foram observados já no primeiro mês de tratamento, mantendo-se até o final do estudo. Houve decréscimo significante nos níveis de colesterol total, triglicerídeos e VLDL-c (p<0.001). Os níveis de LDL-c apresentaram discreta redução (não-significante). Os níveis de HDL-c mostraram decréscimo significante na 24ª semana de tratamento, mas retornaram aos níveis basais na 48ª semana. Não foram observadas modificações significantes no peso e pressão arterial. Os efeitos colaterais relatados incluíram sangramento vaginal, náusea e edema, todos temporários e de intensidade leve. Conclusão: a tibolona representa uma opção para o tratamento dos sintomas climatéricos em mulheres na pós-menopausa, sem alterações relevantes no perfil lipídico e lipoprotéico.<br>Purpose: to evaluate the effects of tibolone on climacteric symptoms and clinical and metabolic variables. Methods: thirty-four postmenopausal women were treated orally with 2.5 mg tibolone daily for 48 weeks and evaluated as to climacteric complaints, clinical aspects such as weight and blood pressure and lipid profile (total cholesterol, HDL-c, LDL-c, VLDL-c and triglycerides). Results: a significant improvement of climacteric complaints was demonstrated by a significant decrease in the Kupperman index (p<0.001) and the mean number of hot flushes (p<0.001) from the first month of treatment onwards. There was a significant decrease in total cholesterol, triglycerides and VLDL-c (p<0.001). The LDL-c levels presented a slight decrease (not significant). The HDL-c levels showed a significant decrease at week 24. However these levels returned to baseline levels at week 48. With regard to the vital signs no change in body weight and blood pressure was measured. The side effects were mild and temporary, vaginal bleeding, nausea and edema being the most common. Conclusion: tibolone may be considered a safe and efficient option to treat climacteric symptoms in postmenopausal women without significant impact on lipid profile
Síndrome do climatério
The climateric is characterized by progressive hipoestrogenism and by tissue and functional alterations that leads the women to aging. The diagnosis approach needs to consider the symptoms originated by estrogenic deficiency and by the more prevalent chronic diseases in this lifetime, for instance, among others, the cardiovascular and osteoporosis diseases, witch need a systematic screening. The therapeutic management must consider the proposition of healthy life habits and, when indicated, pharmacological treatment for estrogenic deficiency or for anothers comorbidities existent. The estroprogestative hormonal therapeutic is a valuable tool to provide health and better quality of life, once obeyed the individualized criterion of the cases, doses, hormonal composition and mainly of the opportunity of intervention. There are nonhormonal alternatives to treat the menopausal symptoms, as the antidepressives and phytoestrogens. It's also advised to combine with regular physical activities and adequate calcium intake. © Copyright Moreira Jr. Editora. Todos os direitos reservados
Síndrome de insuficiência androgênica: critérios diagnósticos e terapêuticos Androgen insufficiency syndrome: diagnostic and therapeutic criteria
A síndrome da insuficiência androgênica na mulher (SIA) desperta, mesmo nos dias atuais, muitas discussões e encerra muitas controvérsias. Sabe-se, no entanto, que os níveis plasmáticos de testosterona declinam progressivamente ao longo do período reprodutivo. Conceitua-se a SIA como o conjunto de sintomas clínicos, a presença de biodisponibilidade diminuída de testosterona e os níveis normais de estrogênios. Entre os principais sintomas, citam-se o comprometimento do bem-estar, o humor disfórico, a fadiga sem causa aparente, o comprometimento do desejo sexual, o emagrecimento e a instabilidade vasomotora em mulheres pós-menopáusicas sob terapêutica estrogênica. Esses sintomas, no entanto, são potencialmente atribuíveis a diferentes etiologias e dificultam o correto diagnóstico na maioria dos casos, ainda que ele seja lembrado com freqüência em pacientes que se submetem à ooforectomia bilateral. O diagnóstico da SIA parece ser essencialmente clínico, não havendo a necessidade das dosagens laboratoriais para a sua comprovação. Não se deve indicar a terapêutica androgênica (TA) em pacientes que não estejam adequadamente estrogenizadas. Considera-se a testosterona o hormônio ideal para a TA. As pacientes com sintomas sugestivos de SIA, excluídas outras causas identificáveis, especialmente se pós-menopáusicas, são candidatas à TA. Não existem dados de segurança sobre a TA em usuárias em longo prazo. A via transdérmica - através de adesivos, cremes e gel - parece ser preferível à oral.<br>The women’s androgen insufficiency syndrome (AIS) arises, even nowadays, many debates and clears a lot of controversies. It is known, however, that the plasmatic levels of testosterone gradually decline through the reproductive period. AIS is appraised as a set of clinical symptoms, bioavailability presence diminished of testosterone and normal levels of estrogen. Among the main symptoms that remind the diagnosis are the well-being impairment, dysphoric mood, the fatigue without apparent cause, the sexual desire impairment, the loss of weight and the vasomotor instability in postmenopausal women receiving estrogen. These, however, are potentially attributable to the different etiologies and make it difficult to give the correct diagnosis in the majority of the cases, even though it is reminded, often, in patients who submit to bilateral oophorectomy. The diagnosis of the SIA seems to be essentially clinical, not having the needs of laboratorial dosages for its proof. It shouldn’t indicate the androgenic therapy (AT) in patients without concomitant estrogen therapy. Testosterone is considered the ideal hormone for AT. Patients with suggestive SIA symptoms, excluded other identifiable causes, especially the post-menopauses ones, are candidates to AT. There are no safety data about AT in long stated period users. The transdermal patches, creams and gel seems to be preferable to the oral formulations